AGRiMED, which owns one of the twelve licenses authorized by the Commonwealth of Pennsylvania to grow and process medical cannabis, today announced a unique and innovative partnership with Univec, Inc (UNVC), a specialty pharmaceutical company to manufacture and distribute its medical cannabis transdermal patch for treatment and relief of approved medical conditions. A transdermal patch adheres or sticks to the skin and delivers a specific dose of medication through the skin and into the bloodstream.
AGRiMED Industries Chief Executive Officer (CEO) Sterling Crockett said, "Today's announcement is consistent with our philosophy of connecting those in need with innovations that heal cleanly, comfortably and sustainably." He added, "We are excited about working with Univec and look forward to sharing the benefits of this partnership with the people of Pennsylvania and beyond."
Dr. David Dalton, Univec's CEO said "Combining Univec's medical and pharmaceutical expertise with AGRiMED Industries' innovative approach to the cannabis marketplace and commitment to its patient focused services makes for a very powerful partnership to expand the treatment options available to the medical community."
AGRiMED Industries, LLC, a Delaware limited liability company, ("AMI" or the "Company"), was created as a holding company to operate within the cannabis industry through its subsidiaries (the "AGRiMED Subsidiaries"). The AGRiMED Subsidiaries are in the business of developing, producing and selling products derived from cannabis in those jurisdictions that have adopted (or in the future will adopt) laws, rules and regulations permitting such products to be produced and sold.
Univec, Inc (UNVC) is a Specialty Pharmaceutical Company that manufactures and distributes specialty pharmaceutical products.